Long-term reduction in IOP due to uneventful surgical procedures in PXG patients

Article

Pseudoexfoliation glaucoma (PXG) patients who underwent uneventful uneventful phacoemulsification, IOL implantation, and trabeculectomy experienced long-term lower IOP and required fewer medications during 10 years.

Pseudoexfoliation glaucoma (PXG) patients who underwent uneventful uneventful phacoemulsification, IOL implantation, and trabeculectomy experienced long-term lower IOP and required fewer medications during 10 years, claims a paper published in the Journal of Cataract and Refractive Surgery.

Dr Bradford J. Shingleton et al., Center for Eye Research and Education, Boston, Massachusetts, USA, performed a retrospective, comparative case series analysis on consecutive eyes with pseudoexfoliation glaucoma (PXG) that underwent uneventful combined phacoemulsification and trabeculectomy. Change in intraocular pressure (IOP), glaucoma medication requirements and logMAR corrected distance visual acuity was compared between the phaco-only group and the combined surgery group.

Mean IOP and glaucoma medication requirements significantly reduced when patients underwent combined surgery, compared to the phaco-only group. Reduction in mean postoperative IOP was more significant in eyes with a higher mean preoperative IOP. Of the eyes included in the combined-surgery group, 13.8% needed subsequent laser trabeculoplasty, glaucoma surgery or a combination of the two.

Combined surgical procedures lead to long-term reductions in IOP and glaucoma medication requirements, as well as fewer 1-day postoperative spikes.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.